{
    "answer": "Novartis's supplementary financial reports do not contain specific comparative immunology segment net sales and currency-based changes for Cosentyx for the full year 2024.",
    "ground_truth": "$6,141,000,000; 23% increase (reported); 25% increase (constant currency)",
    "rewards": [
        0,
        0,
        0,
        0,
        0,
        0
    ],
    "reward_sum": 0,
    "turns": 6,
    "search count": 5,
    "script count": 0,
    "summary count": 0,
    "context lengths": [
        1026,
        1493,
        3346,
        4873,
        6254,
        6955
    ]
}